Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Digital Health Trends 2024 - Implications for Research and Patient Care

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
Global Trends in R&D
Overview through 2020
May 19, 2021
To download files you must give consent to process your personal data by clicking the "Accept" button below.

About the Report

This report examines the trends in pharmaceutical research and development through the end of 2020. It provides an analysis of initiated clinical trials, including the impact of the pandemic and COVID-19-specific research. Research on clinical development productivity is also presented, as well as profiles of the R&D pipeline, R&D funding trends, and characteristics of new drug approvals and launches.

Report Summary

In 2020, the COVID-19 pandemic upended life globally and yet not only did research and development activities largely continue – albeit with disruption – they also resulted in the development of vaccines that are already reaching more than 600 million people. The key drivers of these unprecedented results are visible in benchmarks and trends of various aspects of R&D, providing insight into what other improvements are already underway or could be possible.

  • Funding for early- and late-stage R&D and strategic transactions increased significantly in 2020; aggregate R&D spend for the top 15 companies reached a record high.
  • The number of first-time launches of novel active substances (NAS) reached an all-time high of 66 in 2020 – with success for treatments in oncology and rare diseases.
  • Clinical trial starts increased 8% in 2020, similar growth to the prior three years, with oncology trial starts reaching historically high levels.
  • Overall, clinical trial activity recovered from mid-year 2020 to levels above 2019 – even without COVID-19 trials. 

Key Findings

Exhibit 1: Clinical Trial Activity

Total Number of Clinical Trials by Phase 2010-2020

  • Despite significant societal disruptions from the COVID-19 pandemic, overall clinical trial activity rose 8% in 2020, the fourth consecutive year with an increase above 7%.
  • During the course of 2020, monthly trial starts fell significantly in the first quarter but recovered from mid-year to higher levels than in 2019 even without the COVID-19 trials.
  • While the intention to start trials continued with relatively small disruption, the operation of trials — including recruiting patients and completing studies — may have been disrupted differently, and these trends should be interpreted with caution.
     
Exhibit 20: Clinical Development Productivity by Phase and Overall 2010-2015

The composite Clinical Development Productivity Index rose in 2020 after having declined since 2015

  • Most diseases areas have been declining in clinical development productivity – a composite metric of success rates, clinical trial complexity and trial duration – over the past decade, which embeds the challenges of achieving clinical results in well-satisfied traditional disease areas such as cardiovascular and endocrinology, as well as shifts in research priorities to more difficult areas such as oncology and rare diseases.
  • The increase in the clinical trial productivity index in 2020 was mostly due to an improvement in Phase III trials, widening the gap with Phase I trials, which score significantly lower with this index.
  • Phase II trials have consistently been above the overall index as success rates have been trending up and durations have been trending down, even as complexity has been rising in Phase II as rising numbers of endpoints and eligibility criteria are attributes of these trials.
  • Productivity remains below historic levels as success rates are below the long-term average, while complexity attributes of trials are generally rising, as are trial durations in many diseases.

 

Exhibit 36: Number of Drugs Over Time and Country Share of Early-Stage Pipeline Based on Company Headquarter Location 2005-2020

Drugs from China-headquartered companies have risen to 12% of the early-stage pipeline from 2% a decade ago.

  • The U.S. share of global early-stage R&D has remained relatively stable over the past 15 years.
  • Europe’s share has declined from 33% to 22% over the past five years, while the absolute number of active programs declined by 175 — from 1,604 to 1,429.
  • Products from China-headquartered companies now represent 12% of the early-stage pipeline, up from 2% a decade ago.

 

Exhibit 47: Companies Originating and Filing FDA Regulatory Submissions for NASs and Percent of Launches by NAS Launch Year

 

Emerging biopharma companies originated and launched 40% of all new drugs in 2020, reflecting greater independence in development activities

  • Traditional development and launch models for innovative medicines relied predominantly on large or mid-sized companies, which often partnered with or acquired smaller companies that originated the medicine.
  • That traditional pattern has largely changed in recent years with the last three years having more than 40% of NAS originated and launched by emerging biopharma companies (those with less than $500 million in sales and less than $200 million in R&D spend per year).
Exhibit 42: Percentage of Trials Under-representative of Racial/Ethnic Groups in the U.S. and the Median Share (%) of Subjects Included in Trials by Ethnic Group Per Year, 2015-2020
  • African Americans or races identified as Black account for 13.4% of the U.S. population, while the clinical trials used to approve new medicines had a median participation of only 3% in the past six years and were under-representative 79% of the time from 2015 to 2020.
  • Persons of Asian descent are estimated to comprise 6.5% of the U.S. population, but only in 2015 was the median above this threshold, and 52% of trials in the past six years that were used by the FDA to approve medicines had under-representative participation.
  • Hispanic or Latino ethnicity is estimated at 16% of the U.S. population, and consistently the median participation in trials is less than half that level, though patients may not always identify themselves.
  • Interpretation of race/ethnicity data of approval trials and the representation of the U.S. population is complicated by the role that ex-U.S. subjects often play in those trials that are executed globally.
Contact Us